Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $5.9400 (1.37%) ($5.9400 - $5.9400) on Mon. Apr. 5, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.05% (three month average) | RSI | 40 | Latest Price | $5.9400(1.37%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | AUTL declines -8% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) BNDX(12%) TLT(11%) BND(9%) XLRE(9%) SKYY(8%) | Factors Impacting AUTL price | AUTL will decline at least -2.025% in a week (0% probabilities). TBT(-11%) UNG(-8%) USO(-6%) XLF(-5%) XLB(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.025% (StdDev 4.05%) | Hourly BBV | 0.7 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-7.19(-221.04%) | Inflection Point | Yes | Resistance Level | $6.27 | 5 Day Moving Average | $5.75(3.3%) | 10 Day Moving Average | $5.96(-0.34%) | 20 Day Moving Average | $6.27(-5.26%) | To recent high | -35.9% | To recent low | 8.2% | Market Cap | $310m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |